Clinical observation of Pemetrexed Disodium combined with Cisplatin as the first-line treatment for advanced non-small cell lung cancer

Objective: To compare the efficacy and the safety of Pemetrexed Disodium combined with Cisplatin with those of GEM, PTX or NVB combined with cisplatin for the first-line treatment of advanced non-small cell lung cancer. Methods: Thirty-four cases of patients with advanced non-small cell lung cancer were randomly divided into two groups. In treatment group, 16 patients of advanced NSCLC were received premetrexed 500 mg/m2 d1, in 0.9% sodium chloride injection 100 ml, 10 min intravenous drip, cisplatin 75 mg/m2 d1,2,3. In control group, PTX 150 mg/m2 d1 or GEM 1 000 mg/m2 d1,d8 or NVB 30 mg/m2 d1,d8, in 0.9% sodium chloride Injection 100 ml, intravenous drip, cisplaton 75 mg/m2 d1, 2, 3. Every 21 days as one cycle, the efficacy and adverse reaction after 2 cycles were evaluated. Results: ORR of the treatment group were 25.0% and the control group were 16.7%, there was no significant differences between them (P0.05), the TTP and the OS of the two groups had no significant differences either, but hematological toxicity and gastrointestinal toxicity of the treatment group were obviously less than those of the control group. Conclusion: As the first-line treatment of advanced non-small cell lung cancer, pemetrexed disodium (pem) combined with cisplatin has more stable efficacy, lower toxicity and better tolerability.